

Update to Recommendations in NCIS.Chart



Further Information

Any comments or further information, please contact ncis@cancercontrol.ie

- The NCIS Implementation Group have approved a request for change to add two recommendations to the list of recommendations in the conference form in NCIS.Chart:

- Molecular Biomarker Testing
- Other Recommendation

Molecular Biomarker Testing

A Health Technology Assessment¹ by HIQA to provide advice to the Health Service Executive on alternative gene expression profiling (GEP) tests to Oncotype DX® advised consideration should be given to collecting data on GEP tests, linked to treatment and patient characteristics and outcomes, as part of a national database.

To facilitate documentation of this in NCIS, the NCIS Implementation Group have approved the addition of a recommendation for “Molecular biomarker testing”. This recommendation type is further specified with two options; 1) Oncotype DX Gene Expression Test, and 2) Other.

No.	Recommendation type	Recommendation/location	Information
1.	Molecular biomarker testing	Oncotype DX gene expression test Other	

Other Recommendation

The NCIS MDM User Group proposed a request for change to add a new recommendation of “Other Recommendation” to capture recommendations that do not fit the existing agreed options. The information box can be used to further specify this with free text.

No.	Recommendation type	Recommendation/location	Information
1.	Other Recommendation	in-house specified external not	

¹ A rapid health technology assessment of gene expression profiling tests for guiding the use of adjuvant chemotherapy in early stage invasive breast cancer -February 2023
Health Information and Quality Authority <https://www.hiqa.ie/reports-and-publications/health-technology-assessment/rapid-hita-gene-expression-profiling-tests>